OSCR
Oscar Health Inc
Oscar Health Inc historical holders
total: 5
Ancient Art (Teton Capital) Oscar Health Inc transactions over time
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 2
- Held since:
- 2021 Q4
- Held for:
- 14 quarters
- Latest activity:
- 2025 Q2
Quincy Lee has been an institutional investor in Oscar Health Inc (OSCR) since 2021 Q4. According to 2026 Q1 report, Quincy Lee doesn't hold any shares. The fund/company first acquired OSCR in 2021 Q4, initially purchasing 879,614 shares. Since the initial investment, Ancient Art (Teton Capital) has made 8 more transactions in this position.
When did Quincy Lee exit their OSCR position?
Quincy Lee no longer holds Oscar Health Inc (OSCR). They sold off their entire position in 2025 Q2, closing out an investment that began in 2021 Q4.
When did Quincy Lee first invest in OSCR?
Quincy Lee first invested in Oscar Health Inc (OSCR) in 2021 Q4 at the reported quarter-end price of $7.85 per share, acquiring 879,614 shares in their initial purchase.
What is Quincy Lee's average cost basis for OSCR?
Based on historical transaction data, Quincy Lee's estimated cost basis for Oscar Health Inc (OSCR) is approximately $10.58 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $10.58
- Weighted AVG sell price:
- $14.10
OSCR transactions history by Ancient Art (Teton Capital)
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$13.11
|
|
-100% (-2,950,753)
|
-11.48%
|
|
2024 Q4
|
8.44%
|
2,950,753
|
$13.44
|
$39,658,120
|
+66.84% (+1,182,134)
|
+3.38%
|
|
2024 Q3
|
8.68%
|
1,768,619
|
$21.21
|
$37,512,409
|
+64.67% (+694,607)
|
+3.41%
|
|
2024 Q2
|
4.35%
|
1,074,012
|
$15.82
|
$16,990,870
|
-45.99% (-914,417)
|
-2.92%
|
|
2024 Q1
|
5.97%
|
1,988,429
|
$14.87
|
$29,567,939
|
-46.69% (-1,741,475)
|
-4.32%
|
|
2023 Q4
|
5.69%
|
3,729,904
|
$9.15
|
$34,128,622
|
+33.54% (+936,763)
|
+1.43%
|
|
2023 Q3
|
3.34%
|
2,793,141
|
$5.57
|
$15,557,795
|
+91.95% (+1,337,987)
|
+1.6%
|
|
2022 Q1
|
1.89%
|
1,455,154
|
$9.97
|
$14,508,000
|
+65.43% (+575,540)
|
+0.75%
|
|
2021 Q4
|
0.78%
|
879,614
|
$7.85
|
$6,905,000
|
new
|
+0.78%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.